Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 29 | 2021 | 42 | 9.260 |
Why?
|
| Antiviral Agents | 32 | 2021 | 71 | 8.040 |
Why?
|
| Hepatitis C | 20 | 2022 | 45 | 6.860 |
Why?
|
| Liver Diseases | 14 | 2022 | 35 | 6.030 |
Why?
|
| Hepacivirus | 23 | 2022 | 33 | 4.690 |
Why?
|
| Pregnancy Complications | 8 | 2022 | 52 | 3.900 |
Why?
|
| Liver Transplantation | 9 | 2023 | 96 | 3.820 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 5 | 2024 | 6 | 2.170 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2020 | 14 | 1.890 |
Why?
|
| Liver Cirrhosis | 13 | 2024 | 45 | 1.850 |
Why?
|
| Pregnancy | 13 | 2022 | 340 | 1.710 |
Why?
|
| Ribavirin | 9 | 2016 | 10 | 1.690 |
Why?
|
| Humans | 71 | 2024 | 28462 | 1.580 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2020 | 8 | 1.530 |
Why?
|
| Coinfection | 4 | 2023 | 22 | 1.310 |
Why?
|
| Sulfonamides | 7 | 2020 | 41 | 1.230 |
Why?
|
| Hepatitis B | 5 | 2019 | 12 | 1.210 |
Why?
|
| Interferon-alpha | 5 | 2012 | 32 | 1.200 |
Why?
|
| Polyethylene Glycols | 5 | 2012 | 44 | 1.180 |
Why?
|
| Liver Neoplasms | 4 | 2022 | 105 | 1.170 |
Why?
|
| United States | 19 | 2022 | 2185 | 1.160 |
Why?
|
| HIV Infections | 4 | 2021 | 486 | 1.150 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2022 | 27 | 1.140 |
Why?
|
| Female | 37 | 2024 | 15793 | 1.060 |
Why?
|
| Hepatitis, Autoimmune | 2 | 2024 | 5 | 1.060 |
Why?
|
| Societies, Medical | 3 | 2022 | 152 | 0.980 |
Why?
|
| Carbamates | 9 | 2020 | 9 | 0.960 |
Why?
|
| Quinoxalines | 5 | 2020 | 6 | 0.900 |
Why?
|
| Drug Therapy, Combination | 13 | 2021 | 184 | 0.900 |
Why?
|
| Hepatitis D | 1 | 2023 | 1 | 0.870 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3619 | 0.820 |
Why?
|
| Gastroenterology | 3 | 2017 | 10 | 0.790 |
Why?
|
| Liver Diseases, Alcoholic | 2 | 2021 | 42 | 0.780 |
Why?
|
| Living Donors | 1 | 2021 | 17 | 0.750 |
Why?
|
| Prejudice | 1 | 2021 | 33 | 0.750 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 22 | 0.700 |
Why?
|
| Postoperative Hemorrhage | 1 | 2020 | 24 | 0.690 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 39 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 122 | 0.690 |
Why?
|
| Benzimidazoles | 3 | 2019 | 9 | 0.690 |
Why?
|
| Patient Selection | 1 | 2021 | 209 | 0.680 |
Why?
|
| Kidney Transplantation | 2 | 2018 | 132 | 0.670 |
Why?
|
| Genotype | 10 | 2017 | 352 | 0.660 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2019 | 2 | 0.640 |
Why?
|
| Viral Load | 5 | 2016 | 73 | 0.640 |
Why?
|
| Sofosbuvir | 6 | 2019 | 6 | 0.620 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 6 | 2019 | 6 | 0.620 |
Why?
|
| Adult | 21 | 2021 | 8152 | 0.620 |
Why?
|
| Algorithms | 2 | 2020 | 378 | 0.610 |
Why?
|
| Obesity | 1 | 2021 | 322 | 0.610 |
Why?
|
| Fear | 1 | 2018 | 48 | 0.590 |
Why?
|
| Cholestasis, Intrahepatic | 3 | 2019 | 4 | 0.590 |
Why?
|
| Liver | 3 | 2022 | 160 | 0.580 |
Why?
|
| Middle Aged | 21 | 2021 | 9306 | 0.540 |
Why?
|
| Drugs, Generic | 1 | 2016 | 1 | 0.540 |
Why?
|
| Cyclopropanes | 5 | 2020 | 15 | 0.530 |
Why?
|
| Antacids | 1 | 2016 | 1 | 0.530 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 14 | 0.530 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 2 | 0.520 |
Why?
|
| Sustained Virologic Response | 6 | 2021 | 6 | 0.520 |
Why?
|
| Virology | 1 | 2015 | 2 | 0.510 |
Why?
|
| Length of Stay | 2 | 2016 | 328 | 0.470 |
Why?
|
| Liver Function Tests | 3 | 2022 | 21 | 0.470 |
Why?
|
| Patient Readmission | 1 | 2016 | 133 | 0.470 |
Why?
|
| Young Adult | 9 | 2021 | 2100 | 0.460 |
Why?
|
| Heart Failure | 1 | 2016 | 175 | 0.440 |
Why?
|
| Prevalence | 3 | 2023 | 473 | 0.430 |
Why?
|
| Mass Screening | 5 | 2021 | 185 | 0.430 |
Why?
|
| Male | 23 | 2021 | 15367 | 0.430 |
Why?
|
| Preventive Health Services | 1 | 2013 | 15 | 0.430 |
Why?
|
| Advisory Committees | 1 | 2013 | 24 | 0.430 |
Why?
|
| Prognosis | 5 | 2022 | 824 | 0.420 |
Why?
|
| Risk Factors | 6 | 2023 | 2421 | 0.420 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2021 | 508 | 0.420 |
Why?
|
| Periodicals as Topic | 2 | 2023 | 42 | 0.420 |
Why?
|
| Health Policy | 1 | 2013 | 50 | 0.410 |
Why?
|
| Disease Management | 2 | 2016 | 114 | 0.400 |
Why?
|
| Retrospective Studies | 9 | 2024 | 3612 | 0.400 |
Why?
|
| Hepatitis C Antibodies | 2 | 2022 | 4 | 0.390 |
Why?
|
| Proline | 4 | 2019 | 10 | 0.360 |
Why?
|
| Lactams, Macrocyclic | 4 | 2019 | 5 | 0.360 |
Why?
|
| Imidazoles | 4 | 2020 | 55 | 0.360 |
Why?
|
| RNA, Viral | 4 | 2022 | 45 | 0.350 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 211 | 0.350 |
Why?
|
| Macrocyclic Compounds | 4 | 2019 | 4 | 0.340 |
Why?
|
| Pregnancy Outcome | 2 | 2021 | 18 | 0.340 |
Why?
|
| Drug Resistance, Viral | 4 | 2017 | 14 | 0.340 |
Why?
|
| Aged | 14 | 2020 | 9339 | 0.320 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 166 | 0.310 |
Why?
|
| Cost of Illness | 2 | 2023 | 53 | 0.300 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2008 | 3 | 0.300 |
Why?
|
| Motivation | 3 | 2023 | 99 | 0.290 |
Why?
|
| Fatty Liver | 2 | 2019 | 31 | 0.290 |
Why?
|
| Cohort Studies | 6 | 2021 | 1948 | 0.280 |
Why?
|
| Anemia | 1 | 2008 | 94 | 0.280 |
Why?
|
| Medication Adherence | 2 | 2019 | 81 | 0.270 |
Why?
|
| Benzofurans | 3 | 2020 | 7 | 0.250 |
Why?
|
| Adolescent | 4 | 2020 | 2324 | 0.250 |
Why?
|
| Graft Rejection | 2 | 2018 | 71 | 0.250 |
Why?
|
| Valine | 4 | 2019 | 6 | 0.240 |
Why?
|
| Drug Interactions | 2 | 2015 | 38 | 0.230 |
Why?
|
| Cost-Benefit Analysis | 4 | 2021 | 133 | 0.230 |
Why?
|
| Incidence | 2 | 2020 | 779 | 0.220 |
Why?
|
| Risk Assessment | 3 | 2018 | 676 | 0.220 |
Why?
|
| Pyrrolidines | 3 | 2018 | 11 | 0.220 |
Why?
|
| Hepatitis Delta Virus | 1 | 2023 | 1 | 0.220 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 2 | 0.220 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2023 | 6 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2019 | 1810 | 0.220 |
Why?
|
| Amides | 2 | 2020 | 16 | 0.210 |
Why?
|
| Benzamides | 1 | 2023 | 15 | 0.210 |
Why?
|
| Vaccination | 1 | 2023 | 32 | 0.210 |
Why?
|
| Ritonavir | 3 | 2019 | 3 | 0.210 |
Why?
|
| Uracil | 3 | 2019 | 4 | 0.210 |
Why?
|
| Chronic Disease | 3 | 2020 | 442 | 0.210 |
Why?
|
| Mastocytosis, Systemic | 1 | 2022 | 6 | 0.210 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2022 | 5 | 0.210 |
Why?
|
| RNA | 1 | 2022 | 38 | 0.200 |
Why?
|
| Fibrosis | 1 | 2022 | 30 | 0.200 |
Why?
|
| History, 20th Century | 1 | 2022 | 47 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 4904 | 0.190 |
Why?
|
| Selection Bias | 1 | 2021 | 7 | 0.190 |
Why?
|
| Fertility | 1 | 2021 | 18 | 0.190 |
Why?
|
| Graft Survival | 2 | 2019 | 102 | 0.190 |
Why?
|
| Aminoisobutyric Acids | 2 | 2018 | 2 | 0.190 |
Why?
|
| Leucine | 2 | 2018 | 11 | 0.190 |
Why?
|
| World Health Organization | 1 | 2020 | 11 | 0.180 |
Why?
|
| Tissue Donors | 1 | 2021 | 79 | 0.180 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 13 | 0.180 |
Why?
|
| Anilides | 2 | 2019 | 7 | 0.170 |
Why?
|
| 2-Naphthylamine | 2 | 2019 | 3 | 0.170 |
Why?
|
| Critical Care | 1 | 2022 | 197 | 0.170 |
Why?
|
| Pandemics | 1 | 2022 | 260 | 0.170 |
Why?
|
| Recurrence | 2 | 2011 | 320 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2020 | 81 | 0.170 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 157 | 0.170 |
Why?
|
| Consensus | 2 | 2021 | 98 | 0.170 |
Why?
|
| Drug and Narcotic Control | 2 | 2016 | 3 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 102 | 0.160 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.160 |
Why?
|
| United States Food and Drug Administration | 2 | 2016 | 22 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2019 | 66 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 321 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2018 | 22 | 0.150 |
Why?
|
| Logistic Models | 2 | 2010 | 397 | 0.150 |
Why?
|
| Internationality | 1 | 2018 | 25 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 1868 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 349 | 0.140 |
Why?
|
| Drug Substitution | 1 | 2017 | 4 | 0.140 |
Why?
|
| Time Factors | 3 | 2016 | 1497 | 0.140 |
Why?
|
| Infant, Newborn | 1 | 2019 | 656 | 0.140 |
Why?
|
| Critical Pathways | 1 | 2017 | 21 | 0.140 |
Why?
|
| Psychometrics | 1 | 2018 | 242 | 0.140 |
Why?
|
| Counterfeit Drugs | 1 | 2016 | 1 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 53 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 7 | 0.130 |
Why?
|
| Commerce | 1 | 2016 | 12 | 0.130 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 992 | 0.130 |
Why?
|
| Canada | 1 | 2016 | 51 | 0.130 |
Why?
|
| Ascites | 1 | 2016 | 4 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 33 | 0.130 |
Why?
|
| Safety | 1 | 2016 | 44 | 0.130 |
Why?
|
| Paracentesis | 1 | 2016 | 4 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 8 | 0.130 |
Why?
|
| Fraud | 1 | 2016 | 20 | 0.130 |
Why?
|
| Hospitalization | 2 | 2016 | 322 | 0.130 |
Why?
|
| Eclampsia | 1 | 2016 | 1 | 0.130 |
Why?
|
| HELLP Syndrome | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pre-Eclampsia | 1 | 2016 | 7 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 1216 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2016 | 136 | 0.130 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 32 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2015 | 14 | 0.130 |
Why?
|
| Benchmarking | 1 | 2015 | 38 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2015 | 110 | 0.120 |
Why?
|
| Benzazepines | 1 | 2015 | 4 | 0.120 |
Why?
|
| Isoquinolines | 1 | 2015 | 12 | 0.120 |
Why?
|
| Deficiency Diseases | 1 | 2015 | 2 | 0.120 |
Why?
|
| Comorbidity | 4 | 2018 | 502 | 0.120 |
Why?
|
| Indoles | 1 | 2015 | 38 | 0.120 |
Why?
|
| Liver Failure | 1 | 2015 | 11 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 167 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2017 | 163 | 0.120 |
Why?
|
| Zinc | 1 | 2015 | 44 | 0.120 |
Why?
|
| Phenotype | 1 | 2015 | 308 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 329 | 0.110 |
Why?
|
| Hospitalists | 1 | 2014 | 5 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2014 | 6 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 334 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 78 | 0.110 |
Why?
|
| Health Care Costs | 1 | 2014 | 80 | 0.110 |
Why?
|
| Drug Eruptions | 1 | 2013 | 10 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2016 | 217 | 0.100 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 11 | 0.100 |
Why?
|
| Viral Nonstructural Proteins | 3 | 2017 | 5 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2014 | 126 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 36 | 0.100 |
Why?
|
| Monitoring, Immunologic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2017 | 36 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 494 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 113 | 0.090 |
Why?
|
| Drug Carriers | 1 | 2010 | 7 | 0.090 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2021 | 22 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 117 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 128 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2010 | 274 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 520 | 0.080 |
Why?
|
| Fluorenes | 2 | 2019 | 2 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 236 | 0.070 |
Why?
|
| Hemoglobins | 1 | 2008 | 78 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 939 | 0.070 |
Why?
|
| Hospital Costs | 2 | 2016 | 64 | 0.060 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2022 | 1 | 0.050 |
Why?
|
| Epithelial Cell Adhesion Molecule | 1 | 2022 | 1 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 8 | 0.050 |
Why?
|
| Pyrroles | 1 | 2022 | 24 | 0.050 |
Why?
|
| Hypoxia | 1 | 2022 | 36 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2021 | 15 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2022 | 58 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2019 | 17 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 33 | 0.040 |
Why?
|
| Infection Control | 1 | 2021 | 167 | 0.040 |
Why?
|
| Insurance, Major Medical | 1 | 2018 | 1 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 18 | 0.040 |
Why?
|
| Registries | 1 | 2019 | 191 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 47 | 0.040 |
Why?
|
| Quality of Life | 1 | 2022 | 660 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2017 | 100 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 1 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 52 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2017 | 25 | 0.030 |
Why?
|
| Serine Proteases | 1 | 2016 | 7 | 0.030 |
Why?
|
| Internal Medicine | 1 | 2016 | 30 | 0.030 |
Why?
|
| Career Choice | 1 | 2016 | 30 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 59 | 0.030 |
Why?
|
| Pain Management | 1 | 2018 | 147 | 0.030 |
Why?
|
| Cost Savings | 1 | 2016 | 36 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2018 | 181 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 38 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 726 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 141 | 0.030 |
Why?
|
| Curriculum | 1 | 2016 | 150 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2016 | 146 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 124 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 68 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 179 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2016 | 358 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 255 | 0.030 |
Why?
|
| Drug Industry | 1 | 2014 | 6 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2016 | 247 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 45 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 356 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2014 | 65 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 149 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 719 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 32 | 0.020 |
Why?
|
| Immunoassay | 1 | 2012 | 40 | 0.020 |
Why?
|
| Probability | 1 | 2012 | 91 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 138 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2012 | 934 | 0.020 |
Why?
|